Watch for FDA timing on Yutrepia label amendment approval — the faster it's approved, the sooner Liquidia must exit PH-ILD sales entirely. Also monitor Liquidia's ability to post the required letter of credit within 10 business days (by Oct 27, 2026) and make the $185M payment within 30 business days (by Nov 24, 2026). The Third Circuit's Oct 7 ruling significantly strengthened UTHR's position by reversing the $61.6M damages award against UTHR.
Price Chart
Executive Summary
United Therapeutics (UTHR) entered into a comprehensive settlement agreement with Liquidia Technologies, resolving all pending patent infringement, trade secrets, and antitrust litigation. Liquidia will pay UTHR an aggregate of $330.4 million ($185 million for past damages and $145.4 million in two installments for ongoing sales), while UTHR pays Liquidia $10 million to resolve the RareGen/Sandoz antitrust case. Liquidia must immediately cease all marketing of Yutrepia for PH-ILD and seek FDA label amendment to remove the PH-ILD indication, effectively eliminating the primary competitive threat to UTHR's Tyvaso DPI franchise in the PH-ILD market through at least February 2042.
Key Facts
- Liquidia to pay UTHR $185 million within 30 business days for past damages from Yutrepia PH-ILD sales (June 2, 2025 to execution date)
- Liquidia to pay additional $145.4 million in two equal installments of $72.7 million each (due Jan 31, 2027 and Apr 30, 2027) for ongoing PH-ILD sales
- UTHR to pay Liquidia $10 million to resolve the RareGen/Sandoz antitrust litigation (C.A. No. 2:19-cv-10170)
- Liquidia must immediately file FDA amendment to remove PH-ILD indication from Yutrepia label and cease all marketing/promotion for PH-ILD
- Upon FDA approval of label amendment, Liquidia must immediately cease all sales of Yutrepia bearing the PH-ILD indication
- All pending litigation dismissed with prejudice (except UTHR's trade secrets claims against former executive Robert Roscigno)
- Liquidia covenants not to challenge UTHR's '327 patent (expires Feb 3, 2042) and '782 patent (expires May 14, 2027)
- UTHR grants Liquidia a covenant not to sue for Yutrepia sold for PAH only (non-infringing product)
- Third Circuit on Oct 7, 2026 affirmed summary judgment in UTHR's favor on antitrust claims, reversed breach of contract liability against UTHR
Financial Impact
UTHR receives net $320.4 million in cash payments ($330.4M from Liquidia minus $10M to Liquidia), with $185M due within ~45 days and $145.4M by April 2027. The settlement eliminates the primary competitive threat to UTHR's Tyvaso DPI franchise in the PH-ILD market, which is protected by the '327 patent until Feb 2042.
Risk Factors
- Liquidia may fail to post the required letter of credit within 10 business days, allowing UTHR to terminate the agreement
- Liquidia may struggle to make the $185 million payment within 30 business days given its cash position
- FDA may delay approval of the Yutrepia label amendment, prolonging Liquidia's ability to sell for PH-ILD under current labeling
- Sandoz may not consent to dismissal of the RareGen/Sandoz litigation, potentially complicating the settlement
- Liquidia could attempt to challenge the '327 patent through other means not covered by the non-challenge covenant
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-115723 |
| Document: tm2627546d1_8k.htm | 0001104659-26-115723 |
| Document: 0001104659-26-115723-index-headers.html | 0001104659-26-115723 |
| Document: 0001104659-26-115723-index.html | 0001104659-26-115723 |
| Document: 0001104659-26-115723.txt | 0001104659-26-115723 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | Insider Cluster | $592.84 | awaiting T+5 | awaiting T+5 | $591.20 (−0.28%) |
Oct 22, 2026 5d ago | 8-K | $584.79 | awaiting T+5 | awaiting T+5 | $591.20 (+1.10%) |
Oct 22, 2026 6d ago | Insider Cluster | $587.50 | awaiting T+5 | awaiting T+5 | $591.20 (−0.63%) |
Oct 21, 2026 6d ago | Insider Cluster | $584.79 | awaiting T+5 | awaiting T+5 | $591.20 (+1.10%) |
Oct 20, 2026 7d ago | Insider Cluster | $563.49 | awaiting T+5 | awaiting T+5 | $591.20 (+4.92%) |
Oct 19, 2026 9d ago | Insider Cluster | $553.88 $591.20 | ▲ +6.74% | ▲ +6.66% | $591.20 (+6.74%) |
Oct 16, 2026 11d ago | Insider Cluster | $543.15 $592.84 | ▲ +9.15% | ▲ +9.29% | $591.20 (+8.85%) |
Oct 14, 2026 13d ago | 8-K | $540.03 $563.49 | ▲ +4.34% | ▲ +3.89% | $591.20 (+9.48%) |
Oct 5, 2026 22d ago | Insider Cluster | $541.62 $543.40 | ▼ −0.33% | ▼ −0.47% | $591.20 (−9.15%) |
Oct 2, 2026 25d ago | Insider Cluster | $536.40 $550.10 | ▲ +2.55% | ▲ +2.13% | $591.20 (+10.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers